Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia Cavazzoni, M.D., stepped down in January and joined Pfizer's C-suite as chief ...

Key Takeaways A pill to treat obesity caused liver injury in a clinical trialPfizer said it will stop developing the drug, called danuglipron, as a result Other alternatives to injectable obesity ...

The pharmaceutical giant scrapped development of a once-daily GLP-1 pill after a person involved in the drug’s trial suffered a liver injury.

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

The price of pharmaceuticals will likely go up soon, and generics are poised to be hit the hardest.

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Pfizer Inc. (PFE) is currently at $22.83, up $0.71 or 3.19% --Would be highest close since April 4, 2025, when it closed at $22.97 --On pace for largest percent increase since Dec. 17, 2024, when it ...

Healthcare & Pharmaceuticalscategory US CDC advisers begin review of vaccine guidelines after months-long delay 3:43 PM UTC · Updated ago Healthcare & Pharmaceuticalscategory Bristol Myers' heart ...